2020 BIO Investor Forum Buzz of BIO Winner
Oxidien Pharmaceuticals is a clinical stage biopharma company mitigating recurrent kidney stone disease by treating hyperoxaluria. We are a spin-out with a long development history, essentially Phase-2 ready with an oral, non-absorbed, clinically superior, biologic enzyme. Our next inflection point is Phase 2 read-out (36-42 months out) and we are inviting investors to join towards that goal.
Oxidien Pharmaceuticals is a clinical stage biopharma company mitigating recurrent kidney stone disease by treating hyperoxaluria. We are a spin-out with a long development history, essentially Phase-2 ready with an oral, non-absorbed, clinically superior, biologic enzyme. Our next inflection point is Phase 2 read-out (36-42 months out) and we are inviting investors to join towards that goal.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Metabolic Diseases
Lead Product in Development:
OX-1
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
